ライブ

Promega BlogA Historic Milestone for PROTAC Research: What Vepdegestrant’s FDA Decision Means for Drug Discovery Endpoints NewsGSK goes to China for $1B siRNA deal in Arrowhead's obesity lane PharmaVoiceA new company rises from the ashes of Purdue Pharma CellDisrupted molecular glue complex drives RAS inhibitor resistance CellBiodiversity and biogeography of the multi-kingdom cancer microbiome LabiotechTop biotech deals in April 2026 FierceBiotechGSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat Thermo FisherThermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials - Yahoo Finance FierceBiotechCellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO FierceBiotechBayer buys Perfuse in $2.4B deal for midphase eye disease prospect Endpoints NewsCellCentric raises $220M to get multiple myeloma pill to market FierceBiotechAfter a decade of hype, Najat Khan is bringing Recursion back down to earth

FierceBiotech 2026年5月6日

After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson steppe...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his replacement, Najat Khan, Ph.D., is laser-focused on one thing: turning the amorphous potential of AI into tangible products for patients.